HitGen Delivers Candidates to Cedilla for Cancer Caused by Protein Dysregulation

Chengdu's HitGen announced its discovery collaboration with US-based Cedilla Therapeutics successfully identified small molecule candidates for cancer and other diseases caused by protein dysregulation. HitGen applied its large-scale target libraries to discover compounds that met Cedilla's specified criteria. Cedilla received an exclusive license to these compounds plus IP for further development and commercialization. HitGen will be eligible for future milestone payments and sublicensing income from Cedilla, in addition to research payments and an upfront license fee. More details.... Stock Symbol: (SHA: 688222) Share this with colleagues: // //